March 5, 2026
A new era for transplant-ineligible R/R LBCL patients: what's changing?
Authors
Discussion
Loading...
Member takes
Implication
This review explores new interventions for transplant-ineligible relapsed/refractory large B-cell lymphoma patients, suggesting improved options for care.
Key Points
- To evaluate treatment alternatives for patients with relapsed/refractory large B-cell lymphoma who are not eligible for transplant.
- Review of recent trials including TRANSFORM and ZUMA-7 for CAR T-cell therapy.
- Analysis of the phase II PILOT study focusing on liso-cel effectiveness in medically unfit individuals.
- Discussion of additional therapies such as antibody-drug conjugates and bispecific antibodies.
- CAR T-cell therapy, specifically liso-cel, showed effectiveness in patients typically unfit for autologous stem cell transplantation.
- The TRANSFORM and ZUMA-7 trials revealed superior outcomes for patients receiving CAR T-cell therapy over standard treatments.
- Emerging therapies demonstrate promising response rates for a difficult-to-treat population.
Cite This Study
Tarantini et al. (2026) studied this question.